Efficacy and safety of midodrine in the treatment of dialysis-associated hypotension

Author: Perazella M.A.

Source: Expert Opinion on Drug Safety, Volume 2, Number 1, 1 January 2003 , pp. 37-47(11)

Publisher: Informa Healthcare

Buy & download fulltext article:

OR

Price: $99.00 plus tax (Refund Policy)

Abstract:

Dialysis-associated hypotension is a morbid problem in haemodialysis patients. Employment of midodrine at the start of dialysis has reduced the severity and frequency of hypotensive episodes in these patients. Through selective alpha1-adrenergic receptor-binding, desglymidodrine, the active metabolite of midodrine, raises blood pressure by enhancing venous and arterial tone. This medication has been demonstrated to be effective and safe in the acute and chronic treatment of haemodialysis-associated hypotension in end stage renal disease patients.

Keywords: blood pressure; dialysis-associated hypotension (DAH); haemodialysis; midodrine

Document Type: Review article

Publication date: 2003-01-01

More about this publication?
Related content

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page